{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:05:11Z","timestamp":1759334711104,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.arcmed.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T19:57:11Z","timestamp":1634587031000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relationship Between Acute Phase Reactants and Disability in Guillian-Barr\u00e9 Syndrome During the COVID-19 Pandemic"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6586-2635","authenticated-orcid":false,"given":"Recep","family":"Yevgi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2021.10.002_bib0001","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barr\u00e9 Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0002","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1371\/journal.pone.0000344","article-title":"Guillain-Barr\u00e9 syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database","volume":"2","author":"CC","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0003","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.braindev.2018.01.007","article-title":"Guillain-Barr\u00e9 syndrome and optic neuritis after Mycoplasma pneumoniae infection","volume":"40","author":"Matsunaga","year":"2018","journal-title":"Brain Dev"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0004","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0005","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0006","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/clinchem\/47.3.426","article-title":"Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects","volume":"47","author":"Meier-Ewert","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/(SICI)1098-2825(1999)13:6<273::AID-JCLA4>3.0.CO;2-X","article-title":"Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort","volume":"13","author":"Ritchie","year":"1999","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0008","series-title":"StatPearls","article-title":"Biochemistry, Transferrin","author":"Ogun","year":"2021"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0009","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fpubh.2020.00432","article-title":"D-Dimer Concentrations and COVID-19 Severity: A Systematic Review and Meta-Analysis","volume":"8","author":"Paliogiannis","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/17474086.2020.1831383","article-title":"D-dimer level in COVID-19 infection: a systematic review","volume":"13","author":"Rostami","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0011","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0012","first-page":"283","article-title":"SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19)","volume":"20","author":"Payus","year":"2020","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2020.100669","article-title":"COVID-19 and intracerebral haemorrhage: causative or coincidental?","volume":"35","author":"Sharifi-Razavi","year":"2020","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s13365-021-00957-1","article-title":"Acute transverse myelitis after SARS-CoV-2 infection: a rare complicated case of rapid onset paraplegia","volume":"27","author":"Shahali","year":"2021","journal-title":"J Neurovirol"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/svn-2020-000431","article-title":"Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study","volume":"5","author":"Li","year":"2020","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0016","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0017","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s41983-021-00310-7","article-title":"Guillain-Barre syndrome in 220 patients with COVID-19","volume":"57","author":"Finsterer","year":"2021","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0018","doi-asserted-by":"crossref","first-page":"20939","DOI":"10.1007\/s11356-021-13233-w","article-title":"Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review","volume":"28","author":"Li","year":"2021","journal-title":"Environ Sci Pollut Res Int"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117263","article-title":"Guillain Barr\u00e9 Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series","volume":"420","author":"Sriwastava","year":"2021","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0020","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27 Suppl","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0021","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0022","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41593-020-00758-5","article-title":"Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19","volume":"24","author":"Meinhardt","year":"2021","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0023","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1097\/INF.0000000000003146","article-title":"First Report of SARS-CoV-2 Detection in Cerebrospinal Fluid in a Child With Guillain-Barr\u00e9 Syndrome","volume":"40","author":"Ara\u00fajo","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0025","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.7150\/ijbs.48400","article-title":"Immune Response and COVID-19: A mirror image of Sepsis","volume":"16","author":"L\u00f3pez-Collazo","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0026","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/14728222.2016.1086751","article-title":"Are Th17 cells and their cytokines a therapeutic target in Guillain-Barr\u00e9 syndrome?","volume":"20","author":"Wu","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1684\/ecn.2019.0424","article-title":"Autoimmunity and cytokines in Guillain-Barr\u00e9 syndrome revisited: review of pathomechanisms with an eye on therapeutic options","volume":"30","author":"Ebrahim Soltani","year":"2019","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0028","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1007\/s10072-020-04787-7","article-title":"HLA and immunological features of SARS-CoV-2-induced Guillain-Barr\u00e9 syndrome","volume":"41","author":"Gigli","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0029","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.arcmed.2021.10.002_bib0030","doi-asserted-by":"crossref","first-page":"e13024","DOI":"10.1111\/cpr.13024","article-title":"Bioinformatic analyses hinted at augmented T helper 17 cell differentiation and cytokine response as the central mechanism of COVID-19-associated Guillain-Barr\u00e9 syndrome","volume":"54","author":"Li","year":"2021","journal-title":"Cell Prolif"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921002009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921002009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:51:40Z","timestamp":1759261900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440921002009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0188440921002009"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.10.002","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship Between Acute Phase Reactants and Disability in Guillian-Barr\u00e9 Syndrome During the COVID-19 Pandemic","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}